Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which ...

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio ...

Nishit Agarwal exemplifies excellence in Biomedical AI and Signal Processing with extensive experience in developing cutting-edge clinical AI solutions and biomarker development. His expertise spans ...

Ulrik brings extensive experience from the pharmaceutical and data science sectors, having previously held Director level positions at Novo Nordisk, working in Denmark and Japan, and as a data ...

Clinical trials are considered the cornerstone of health care research because they provide the most reliable and scientifically rigorous method for evaluating new medical interventions.

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio is ...

The NLST demonstrated a 20% reduction in lung cancer mortality through annual LDCT screening, leading to its inclusion in clinical guidelines in 2013. However, despite two decades of outreach, only 18 ...